Login to Your Account

Other News To Note

Wednesday, February 29, 2012
• pSivida Corp., of Watertown, Mass., said the UK's Medicines and Healthcare Products Regulatory Agency accepted for reivew the marketing application for diabetic macular edema (DME) drug Iluvien (fluocinolone acetonide intravitreal insert) via the European decentralized procedure. Iluvien will be indicated for vision impairment associated with chronic DME considered insufficiently responsive to other therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription